$226,323,195
to ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI
AIDS MALIGNANCY CONSORTIUM (AMC)
Verbatim from USAspending.gov. Capitalization, abbreviations, and codes are unchanged.
What the model surfaced from this award
Funds the AIDS Malignancy Consortium to conduct research on cancers associated with HIV/AIDS at Mount Sinai.
Addresses critical health disparities in HIV-related malignancies and advances precision oncology for immunocompromised populations.
Drives demand for specialized laboratory equipment, diagnostic tools, and pharmaceutical research capabilities in academic medical centers.
U.S. leadership in HIV/AIDS and cancer research maintains competitive advantage in precision medicine and therapeutic development.
Generated by award_classification v2.0.0 via claude-haiku-4-5-20251001 on 2026-05-15. Cost: $0.002179.
- 2026-03-19THIS CONTRACT WILL SUPPORT COMPONENT A OF THE COLLABORATIVE INFLUENZA VACCINE INNOVATION CENTERS (CIVICS) PROGRAM TO DESIGN AND EVALUATE INNOVATIVE INFLUENZA VACCINE APPROACHES, BASED ON PRINCIPLES OF INFLUENZA IMMUNITY, THAT ACHIEVE DURABLE, ROBUST$107.5M
- 2026-04-24MSSM CEIRR - THIS CONTRACT WILL SUPPORT THE NIAID CENTERS OF EXCELLENCE FOR INFLUENZA RESEARCH AND RESPONSE.$73.9M
- USAspending.gov — all awards for this UEI →
- SAM.gov entity registration →
- Award record ingested from usaspending. Source identifier ASST_NON_UM1CA121947_075.
The Buildout does not edit federal records. Any inaccuracy reflects the upstream source; it will update here when corrected there.